Published in Curr Opin Hematol on July 01, 2015
The ubiquitin system. Annu Rev Biochem (1998) 43.36
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol (1999) 9.92
Involvement of the bcl-2 gene in human follicular lymphoma. Science (1985) 8.19
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer (2006) 6.76
c-MYC: more than just a matter of life and death. Nat Rev Cancer (2002) 6.73
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol (1999) 5.40
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 5.37
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity (2000) 5.36
p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol (1999) 4.98
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J (2004) 4.95
Cell death. N Engl J Med (2009) 4.75
The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol (2009) 4.61
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Frequent inactivation of A20 in B-cell lymphomas. Nature (2009) 4.22
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem (2003) 3.68
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab (2005) 3.43
Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol (2008) 3.31
Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell (2004) 3.27
Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A (1998) 3.26
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood (2009) 3.10
Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell (2006) 3.08
Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol (2005) 3.08
The genetic landscape of mutations in Burkitt lymphoma. Nat Genet (2012) 3.03
c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol (2000) 2.96
Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell (2000) 2.95
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood (2008) 2.94
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol (2004) 2.90
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A (2000) 2.81
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med (2009) 2.80
BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A (1998) 2.76
Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol (2000) 2.67
BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res (2001) 2.57
SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol (2001) 2.56
Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A (2001) 2.55
A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol (2012) 2.47
Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A (2003) 2.45
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood (2007) 2.28
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol (2010) 2.27
Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol (2011) 2.27
Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A (1995) 2.13
c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood (2000) 2.08
A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One (2006) 2.05
Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc Natl Acad Sci U S A (1993) 2.05
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood (2009) 2.04
DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci Signal (2010) 2.04
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood (2009) 1.99
Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med (2007) 1.99
F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature (2009) 1.93
Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology (2002) 1.90
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev (2004) 1.88
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood (2001) 1.84
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature (2012) 1.79
Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev (2012) 1.78
Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78
Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell (2008) 1.78
Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev (2007) 1.71
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 1.66
Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood (2009) 1.64
IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol (2010) 1.64
Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia (2009) 1.60
Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell (2014) 1.59
Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med (1988) 1.59
βTrCP regulates BMI1 protein turnover via ubiquitination and degradation. Cell Cycle (2011) 1.58
SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase. EMBO J (2000) 1.55
Roles of F-box proteins in cancer. Nat Rev Cancer (2014) 1.51
The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res (2010) 1.50
Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol (2012) 1.47
Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol (2011) 1.46
Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia (2008) 1.43
The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood (1988) 1.42
Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res (1993) 1.41
The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene (2010) 1.41
MYC and aggressive B-cell lymphomas. Adv Anat Pathol (2011) 1.38
A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia (2009) 1.38
Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. Mol Cell Biol (2008) 1.37
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia (1996) 1.36
Therapeutic targeting of MLL. Blood (2009) 1.36
Notch signaling: switching an oncogene to a tumor suppressor. Blood (2014) 1.32
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev (2014) 1.30
EZH2 in normal and malignant hematopoiesis. Leukemia (2013) 1.28
Regulation and Role of EZH2 in Cancer. Cancer Res Treat (2014) 1.27
The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol Rev (2012) 1.26
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood (2012) 1.25
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell (2010) 2.50
Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell (2010) 2.25
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 1.66
Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci U S A (2011) 1.65
Anaplastic Large Cell Lymphoma. Am J Clin Pathol (2007) 1.64
Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS. Lab Invest (2005) 1.63
Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood (2002) 1.33
Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop (2009) 1.31
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood (2003) 1.28
Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene (2004) 1.24
Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem (2010) 1.16
Commentary on the WHO classification of tumors of lymphoid tissues (2008): indolent B cell lymphomas. J Hematop (2009) 1.03
Regulation of the copper chaperone CCS by XIAP-mediated ubiquitination. Mol Cell Biol (2010) 1.03
The ubiquitin-conjugating enzyme (E2) Ube2w ubiquitinates the N terminus of substrates. J Biol Chem (2013) 1.03
High-resolution melting analysis for detection of internal tandem duplications. J Mol Diagn (2004) 1.01
Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2013) 0.99
Analysis of BCL6-interacting proteins by tandem mass spectrometry. Mol Cell Proteomics (2005) 0.98
The molecular pathology of primary immunodeficiencies. J Mol Diagn (2004) 0.98
Sequence alignment by cross-correlation. J Biomol Tech (2005) 0.93
Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics (2007) 0.92
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood (2009) 0.91
High-throughput analysis of protein/peptide complexes by immunoprecipitation and automated LC-MS/MS. J Biomol Tech (2003) 0.91
Analysis of phosphatase and tensin homolog tumor suppressor interacting proteins by in vitro and in silico proteomics. Proteomics (2005) 0.91
Conjugated polyelectrolyte-antibody hybrid materials for highly fluorescent live cell-imaging. Adv Mater (2012) 0.90
Proteomics in pathology research. Lab Invest (2004) 0.90
Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas. J Hematop (2009) 0.88
Comparative microarray analysis of gene expression during activation of human peripheral blood T cells and leukemic Jurkat T cells. Lab Invest (2003) 0.88
Identification of proteins released by follicular lymphoma-derived cells using a mass spectrometry-based approach. Proteomics (2006) 0.88
Microarray analysis of B-cell lymphoma cell lines with the t(14;18). J Mol Diagn (2002) 0.88
A bimolecular affinity purification method under denaturing conditions for rapid isolation of a ubiquitinated protein for mass spectrometry analysis. Nat Protoc (2010) 0.87
Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol Cell Proteomics (2004) 0.87
Hybridization-induced dequenching of fluorescein-labeled oligonucleotides: a novel strategy for PCR detection and genotyping. Am J Pathol (2003) 0.87
Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma (2005) 0.87
Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. Mod Pathol (2003) 0.86
Ordered assembly of heat shock proteins, Hsp26, Hsp70, Hsp90, and Hsp104, on expanded polyglutamine fragments revealed by chemical probes. J Biol Chem (2011) 0.86
P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas. J Hematop (2009) 0.85
Utility of linearly amplified RNA for RT-PCR detection of chromosomal translocations: validation using the t(2;5)(p23;q35) NPM-ALK chromosomal translocation. J Mol Diagn (2004) 0.84
T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. Am J Surg Pathol (2004) 0.83
Role of the ubiquitin proteasome system in hematologic malignancies. Immunol Rev (2015) 0.83
Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma. Mod Pathol (2004) 0.83
Expression of the Rho-family GTPase gene RHOF in lymphocyte subsets and malignant lymphomas. Br J Haematol (2005) 0.81
Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma. Mol Cell Proteomics (2006) 0.81
Evaluation of enrichment techniques for mass spectrometry: identification of tyrosine phosphoproteins in cancer cells. J Mol Diagn (2007) 0.81
Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Diagn Mol Pathol (2012) 0.81
Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS. Lab Invest (2007) 0.80
Detection of MPL mutations by a novel allele-specific PCR-based strategy. J Mol Diagn (2013) 0.80
Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma. Hum Pathol (2007) 0.80
Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma. Leuk Res (2007) 0.79
A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations. J Mol Diagn (2013) 0.79
Ubiquitin ligases in malignant lymphoma. Leuk Lymphoma (2004) 0.78
Requisite analytic and diagnostic performance characteristics for the clinical detection of BRAF V600E in hairy cell leukemia: a comparison of 2 allele-specific PCR assays. Appl Immunohistochem Mol Morphol (2015) 0.78
Annotated proteome of a human T-cell lymphoma. J Biomol Tech (2005) 0.77
Analytical characteristics of cleavable isotope-coded affinity tag-LC-tandem mass spectrometry for quantitative proteomic studies. J Mol Diagn (2006) 0.77
Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer. Mol Cell Proteomics (2013) 0.76
Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. Hum Pathol (2009) 0.76
Quantitative proteomic analysis of follicular lymphoma cells in response to rituximab. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.76
Molecular diagnostics of T-cell lymphoproliferative disorders. Cancer J (2014) 0.76
Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule. J Hematop (2009) 0.75
5'-(RACE) identification of rare ALK fusion partner in anaplastic large cell lymphoma. J Mol Diagn (2003) 0.75
Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis. Mol Diagn Ther (2006) 0.75
Gene expression profiling of cell lines derived from T-cell malignancies. FEBS Lett (2002) 0.75
BCL-2 is consistently expressed in hyperplastic marginal zones of the spleen, abdominal lymph nodes, and ileal lymphoid tissue. Am J Surg Pathol (2003) 0.75